



# NATIONAL INSTITUTE OF BIOLOGICALS

Ministry of Health & Family Welfare  
Government of India



## NEWSLETTER

ISSUE : 1 | JANUARY - MARCH, 2026



**34<sup>th</sup> Foundation Day Celebrations of the National Institute of Biologicals (NIB), Noida**  
*Advancing Excellence in Regulatory Science, Quality Assurance, and Public Health*  
**27<sup>th</sup> January, 2026**

## Director's Desk



It gives me immense pleasure to present the January–March 2026 issue of the National Institute of Biologicals (NIB) Newsletter, highlighting another productive quarter marked by scientific excellence, institutional growth, and continued commitment to safeguarding public health.

As India's apex regulatory laboratory for biological products and a notified Central Drugs Laboratory and Central Medical Device Testing Laboratory, NIB remains steadfast in its mission to ensure the quality, safety, and efficacy of biological medicines, vaccines, blood products, and in-vitro diagnostics.



NIB continued to expand its regulatory testing mandate during the quarter by incorporating new biological products into its notified list for quality control testing. New additions included blood grouping reagents, dengue monoclonal antibody, dostarlimab, teclistamab, combination in-vitro diagnostic devices, additional formulations of darbepoetin alfa and trastuzumab, among others, taking the total number of biologicals under NIB's regulatory quality control ambit to 340. This expansion reflects the Institute's commitment to keeping pace with advances in biological medicines and diagnostics while strengthening public health through robust regulatory quality assurance.

Our 34<sup>th</sup> Foundation Day provided an opportunity to reflect on NIB's journey and reaffirm our unwavering commitment to safeguarding public health by assuring the quality, safety, and efficacy of biological products. The scientific deliberations and interactions with subject experts reinforced our vision of building a future-ready institution capable of addressing emerging public health challenges.

Capacity building continues to remain one of our core strengths. Through specialized training programmes, workshops, and scientific lectures, the Institute has continued to enhance the competencies of its scientists and stakeholders while fostering a culture of continuous learning and regulatory excellence.

I am particularly pleased to note the remarkable achievements of our scientists, whose awards, invited lectures, publications, expert committee participation, and national and international engagements reflect the high standards of scientific excellence nurtured at NIB. These accomplishments not only bring recognition to the Institute but also contribute significantly to strengthening India's regulatory and public health ecosystem.

This quarter also witnessed the celebration of International Women's Day, recognizing the remarkable contributions of women scientists and staff to NIB's mission. The celebration reflected our commitment to fostering an inclusive workplace that promotes equality, mutual respect, and excellence in science, in line with the vision of 'Give to Gain'.

As we move forward, NIB remains committed to advancing scientific excellence, strengthening regulatory systems, and fostering meaningful collaborations to address the evolving needs of the healthcare sector. Guided by our mandate and driven by the dedication of our scientists, technical personnel, and support staff, we will continue to uphold the highest standards of quality assurance for biological products in the service of the nation.

With Best Wishes

**(Dr. Neelima Mishra)**

| Contents in this Issue                                                                          | Page No. |
|-------------------------------------------------------------------------------------------------|----------|
| Article: Dengue and Importance of NS1 glycoprotein in its Early Clinical Diagnosis              | 3-4      |
| Awards/Conferences                                                                              | 4        |
| Quality Assurance / Quality Control of Bio-Therapeutics, Prophylactics and In-Vitro Diagnostics | 5        |
| Nomination/ Participation of NIB Scientists in various Meetings / Workshops                     | 6-8      |
| Events Under Annual Capacity Building Plan-2025-26 for NIB Officials                            | 8        |
| Trainings                                                                                       | 8        |
| Publications                                                                                    | 8        |

### Editorial Team

|                              |                                           |                                      |                                             |
|------------------------------|-------------------------------------------|--------------------------------------|---------------------------------------------|
| Dr. Charu M. Kamal<br>Editor | Ms. Sudha V. Gopinath<br>Associate Editor | Dr. Suresh Kumar<br>Associate Editor | Dr. Rajesh Kumar Sharma<br>Associate Editor |
|------------------------------|-------------------------------------------|--------------------------------------|---------------------------------------------|

## ARTICLE

**Dengue and Importance of NS1 glycoprotein in its Early Clinical Diagnosis**


*Dr. Manoj Kumar@mkrjput@nib.gov.in, Scientist Grade-II, is the Head of the newly formed Dengue Testing Laboratory. He has 19 years of experience in the quality testing of various biologicals, including immunodiagnosics, molecular diagnostics, and therapeutics. Previously, as the independent In-charge of the Molecular Diagnostic Laboratory (MDL), he established the laboratory and successfully led it to achieve ISO/IEC 17025 accreditation.*



Dengue infection or break-bone fever is a vector-borne disease. This viral infection is mainly transmitted by female *Aedes aegypti* mosquito. Any of the four serotypes of Dengue virus viz. DENV1, DENV2, DENV3 or DENV4 or in combination may cause acute febrile illness, which is characterised as dengue infection in correlation with specific diagnostic markers. As per WHO, the cases of dengue are detected in every continent except Antarctica and it is endemic to 100 plus countries. The incidences of Dengue viral infection are more common in subtropical and tropical regions. Due to nature of infection and its symptoms, several mild and other misdiagnosed cases are missed and it is hard to get actual data on the number of cases per year. WHO estimated that globally, around 400 million dengue infections occur annually and out of these 500000 patients develop severe symptoms leading to deaths of 25000 patients.

A huge global resurgence of Dengue is observed in last 20 years and the cases have risen to 10-fold. The climate change, rapid urbanization and increased movement of people to new geographic regions may be among the factors responsible for increase in the dengue infection rate. Warm and humid weather is favourite habitat for *Aedes aegypti* breeding which is readily available in high-density urban areas due to poor water management. In year 2023, Bangladesh and Latin America witnessed a record-breaking year for dengue infections. In Bangladesh, this outbreak was driven by DENV2 serotype. A significant number of cases are reported from European countries. Dengue infection is no longer restricted to tropical areas, with the adaptability of the *Aedes* mosquito to new environmental conditions, the dengue virus getting introduced into new areas. In areas, where more than two Dengue serotypes are causing infection, the subsequent infection increases the severity of the disease and the region is regarded as hyperendemic.

Till date, no specific antiviral drug or licensed vaccine is available for treatment of dengue infection in India. In view of it, the surveillance and early detection becomes crucial. National Dengue Day is observed in India on May 16<sup>th</sup> to raise awareness about dengue prevention, educate the public on symptoms, and encourage community action against mosquito breeding before the monsoon season. This was initiated by the Ministry of Health and Family Welfare in 2010, with its aims to reduce the mortality rate of this deadly, yet preventable, viral disease.




**Figure 1: Seasonal trend of Dengue Cases in India 2018-2022 (Source: National Guidelines for clinical management of Dengue fever 2023, NCVBDC)**

In India, it is seen that the number of cases of dengue increases from July to November i.e. seasonal pattern is shown by this disease and numbers of cases vary from season to season as shown in Fig 1. It appears that the number of cases is highest after monsoon. In western and southern regions dengue cases are perennial. This may be due humid weather after rainy season, and in the western and southern regions the environmental conditions appear favourable for mosquito breeding.

Early diagnosis of Dengue is critical because the disease can rapidly progress from a mild febrile illness to severe, life-threatening complications such as Dengue Haemorrhagic Fever and Dengue Shock Syndrome. Timely identification directly impacts patient survival, outbreak control, and healthcare resource management. The mortality can be reduced from >20% (untreated severe dengue) to <1% by the timely diagnosis, immediate fluid management and platelet monitoring. It will helpful in avoiding unnecessary use of antibiotics, supporting vector control strategies and health authorities to track and contain epidemics.

| Dengue Diagnostic Methods |                    |                             |                                                |                                                                             |
|---------------------------|--------------------|-----------------------------|------------------------------------------------|-----------------------------------------------------------------------------|
| Diagnostic test           | Target             | Days post on set of fever   | Benefit(s)                                     | Limitation(s)                                                               |
| NS1 Antigen               | Dengue NS1 protein | 0 to 7 day                  | Early active infection detection               | Less sensitive later, Cross reactivity with yellow fever                    |
| RT-PCR                    | Dengue RNA         | -2 to 7 day                 | Highly accurate                                | Expensive, RNA is fragile, Requires specialised Lab & high skilled manpower |
| IgM ELISA                 | IgM Antibody       | Day 5+ (Reliable detection) | Indicates recent infection                     | Cross reactivity with yellow fever & West Nile infection                    |
| IgG ELISA                 | IgG Antibody       | Late phase                  | Indicates prior infection & potential immunity | Past infection, Cross reactivity with yellow fever & Japanese encephalitis  |



**Figure 2: Appearance of various dengue diagnostic markers (Source: Kabir et al., 2021)**

### NS1, the early phase direct dengue detector :

The 46-55 kDa non-structural 1 (NS1) glycoprotein of Dengue virus is secreted by host cells into the blood stream during early phase of dengue infection. It is frequently reported in the range of 0.5 to 2 µg/ml in the serum. The diagnostic tests based on dengue NS1, directly detect its NS1 antigenic protein and can identify infection before the appearance of antibodies. NS1 based tests are available as RDT and ELISA kits. NS1 RDT can give result within 20-30 minutes and NS1 ELISA in 2-3 hours. The IgM antibodies generally appear 5 days after onset of fever, and are generated in human body in response to dengue antigen. The IgM and or IgG antibody-based tests are indirect diagnostic test for dengue infection. Generally, generation of IgM indicates patient's recovery response to infection. IgG appears later in primary infections, and it also indicates past infection or secondary dengue infection. Therefore, NS1 test is more sensitive and specific than antibody-based tests especially when the symptoms are non-specific (fever, headache) and IgM/IgG are often negative.

### REFERENCES :

1. National Guidelines for clinical management of Dengue fever 2023, NCVBDC
2. Dengue and severe dengue. WHO. March 2023.
3. Dengue Global situation. WHO. February 2024.
4. De Santis O, Bouscaren N, Flahault A (2023). "Asymptomatic dengue infection rate: A systematic literature review". Heliyon 9 (9) e20069. doi:10.1016/j.heliyon.2023.e20069.
5. Olalekan Chris Akinsulie, Ibrahim Idris. (2024) Global re-emergence of dengue fever: The need for a rapid response and surveillance. The Microbe, Volume 4, 100107.
6. Kabir MA, Zilouchian H, Younas MA, Asghar W. Dengue Detection: Advances in Diagnostic Tools from Conventional Technology to Point of Care. Biosensors (Basel). 2021 Jun 23;11(7):206.
7. Josephine Diony Nanda, Trai-Ming Yeh, Rahmat Dani Satria, Ming-Kai Jhan, Yung-Ting Wang, Ya-Lan Lin et al., 2025. Dengue virus non-structural protein 1 binding to thrombin as a dengue severity marker: Comprehensive patient analysis in south Taiwan. Journal of Microbiology, Immunology and Infection. Volume 58, Issue 2, Pages 198-208.

## AWARDS / CONFERNCES

- Dr. Gauri Misra, Scientist Grade-I, has been awarded the prestigious Edward Kennedy Memorial award for her outstanding contributions in the field of oncology in the 9<sup>th</sup> Edition of World Cancer Congress-2026, held at JNU Convention Centre, New Delhi, India, from 20<sup>th</sup> to 21<sup>st</sup> March, 2026.



- Ms. Suchitra, Junior Scientist, IDKL, has participated and won First Prize in Quiz Competition organized by AcSIR – NIB Ph. D scholar's science club on the occasion of National Science Day on 27<sup>th</sup> February, 2026 at NIB.
- Mr. Rajeev Kumar and Md. Daud Ali, Junior Scientists, IDKL, have participated and won First Prize in the Group Discussion Competition organized by the AcSIR–NIB Ph.D. Scholars' Science Club on the occasion of National Science Day, under the theme "Women in Science: Catalysing Viksit Bharat", held on 27<sup>th</sup> February, 2026 at NIB.

## 34<sup>th</sup> FOUNDATION DAY CELEBRATION OF NATIONAL INSTITUTE OF BIOLOGICALS (NIB), NOIDA

The 34<sup>th</sup> Foundation Day Celebrations of National Institute of Biologicals (NIB), Noida, held on 27<sup>th</sup> January 2026, provided a platform to reflect on the Institute's achievements and reaffirm its commitment to excellence in regulatory science, quality assurance, and public health. The programme commenced with a welcome address by the Director, Dr. Neelima Mishra, followed by a keynote lecture by Dr. Sarabjit S. Chadha, Country Director, India & Regional Director, Asia, FIND, on "Shaping the Future of Quality Diagnostics – Collaborative Vision for NIB & FIND." The celebrations also featured expert lectures on publishing in high-impact journals, the national biosafety regulatory framework, and mind management for enhanced productivity, delivered by eminent academicians and subject experts. The event fostered scientific exchange, strengthened collaborative partnerships, and reinforced NIB's vision of advancing innovation, regulatory excellence, and capacity building in support of India's public health priorities.



## INTERNATIONAL WOMEN'S DAY

NIB celebrated International Women's Day on 9<sup>th</sup> March, 2026 with the theme 'Give to Gain'. The programme was organized by the Committee for Women Welfare (CWW) and included a poster-making competition aimed at raising awareness about the provisions of the POSH Act, 2013. A key highlight of the event was an invited talk delivered by the Chief Guest, Dr. Alka Sharma, Scientist H, Additional Director General, ICMR. The celebration also featured a cultural programme during which awards were presented in various categories.



- NACO-NRL, NIB organized a one-day EQAS workshop on 30<sup>th</sup> January, 2026 for the distribution of HIV serology proficiency testing panels (Round II, 2025–26) to State Reference Laboratories across Uttar Pradesh & Uttarakhand. Thesession was chaired by Dr. Akanksha Bhisht, Head -IDKL & Hemovigilance along with Dr. R.K. Sharma, Head- BKL &NRL- In-charge, and Dr. Pankaj Ghatbandhe, Project Manager, SHARE India, New Delhi. The programme also included adedicated training session on the NACO Prayogshala platform, conducted by Dr. Ghatbandhe for participating laboratory technicians.
- Draft report of EDQM Proficiency testing study “PTS263: Immunoglobulin protein composition has been received by Blood Products Laboratory and as per draft report Lab scored satisfactory results.
- Standardization of an In-Vitro Assay for the Potency control of Human Rabies Vaccine by ELISA was conducted by the Department of Biological Standardization, OMCL Network & Healthcare, EDQM, Council of Europe under Biological Standardization Program (BSP-148), The phase-3 study has been successfully completed & the Vaccine & Antisera Laboratory received draft report on 19<sup>th</sup> February, 2026 for review & the report was subsequent reviewed and accepted.



## NOMINATION/ PARTICIPATION OF NIB SCIENTISTS IN VARIOUS MEETINGS/ WORKSHOPS

- Mrs. Kanchan Ahuja, Scientist Grade- II, and Head, attended release of “Indian pharmacopeia at BR Ambedkar International Centre Janpath, New Delhi on 2<sup>nd</sup> January, 2026 organized by Indian Pharmacopeia Commission, Ghaziabad.
  - The Honourable Chairman and Members of the Committee on Papers Laid on the Table, Rajya Sabha, visited the Recombinant Products Laboratory on 7<sup>th</sup> January, 2026. During the visit, the laboratory team showcased ongoing quality control activities to highlight the rigorous standards maintained in recombinant products evaluation. The lab also shared details of ongoing research activities, emphasizing the lab's commitment to innovation and excellence in recombinant product development with the distinguished guests.
  - Mrs. Kanchan Ahuja, Scientist Grade- II, attended Winter Dialogue on Responsible AI for Synergistic Excellence (RAISE) organized by NIIMS University Rajasthan Jaipur on 12<sup>th</sup> January, 2026 at IIT Research and Innovation Park, New Delhi.
  - Dr. Anoop Kumar, Junior Scientist, delivered an invited lecture on “Immuno-informatics & its application” in DBT-funded National Workshop titled “Next Generation Sequencing and Machine Learning in Bioinformatics,” held from 12<sup>th</sup> to 14<sup>th</sup> January, 2026 organized by the Bioinformatics Center, School of Agricultural Biotechnology, Punjab Agricultural University, Ludhiana.
  - Dr. Shikha Yadav, Scientist Grade-I and Head, attended meeting of the Council of Accreditation, Asia-Pacific Section, AAALAC International in Petchaburi, Thailand from 16<sup>th</sup> to 19<sup>th</sup> January, 2026.
  - Dr. Birendra Kumar, Junior Scientist, attended Two-Days International Conference on Indian Knowledge System: Various Contexts from 20<sup>th</sup> to 21<sup>st</sup> January, 2026 at Maharaja Surajmal Brij University, Bharatpur, Chak Sakeetra, Kumher, Rajasthan.
  - Dr. Gauri Misra, Scientist Grade- I and Head, as an expert, attended the 43<sup>rd</sup> Technical Advisory Committee (TAC) Meeting of MedTech Mitra virtually held on 22<sup>nd</sup> January, 2026.
  - Dr. Gauri Misra, Scientist Grade- I, nominated as a panellist from NIB, attended the ClinLab Conference 2026, organized by the Association of Diagnostics Manufacturers of India (ADMI), at Bharat Mandapam, New Delhi, on 30<sup>th</sup> January, 2026. The conference was organized on the theme “Building Diagnostics Resilience: Strengthening India's Supply Chain Future.” Dr. Misra participated as an expert panellist in the panel discussion titled “Policies that Power Diagnostics: Catalyzing India's Supply Chain Future.”
- 



- Dr. Gauri Misra, Scientist Grade- I and Head, as the principal nominated member from NIB attended virtually the 21<sup>st</sup> meeting of Medical Biotechnology & Medical Nanotechnology sectional Committee MHD20 of Bureau of Indian Standards (BIS), Noida on 28<sup>th</sup> January, 2026.
- Ms. Gurminder Bindra, Scientist- III, participated as subject expert in Joint Inspection for grant of permission in Form CT11 to manufacture Recombinant Human Erythropoietin alfa injection, 10000IU for clinical trial purpose at M/s Kwaliti Pharmaceuticals Limited, Village Nag Kalan, Majitha Road, Amritsar, Punjab on 4<sup>th</sup> and 5<sup>th</sup> February, 2026
- Dr. Shikha Yadav, Scientist Grade-I and Head, delivered lecture on “Advances in the Refinement of Experimental Procedures in Small Laboratory Animals,” at All India Institute of Ayurveda (AIIA), New Delhi, on 6<sup>th</sup> February, 2026.
- Dr. Gauri Misra, Scientist Grade- I and Head, as an external expert attended the meeting on Re-deliberation of the Expert comments on Clinical Performance Evaluation application in Form MD-24 for New In-vitro Diagnostics Medical Device i.e., RICCA, SARS-CoV-2 Detection kit, virtually on 11<sup>th</sup> February, 2026, organized by CDSCO.
- Dr. Gauri Misra, Scientist Grade- I and Head, nominated as DBT nominee of the Institutional Biosafety Committee (IBSC) Constituted at Government Institute of Medical Science (GIMSN-1514) Kasma, Gautam Buddha Nagar on 11<sup>th</sup> February, 2026.
- Dr. Charu Mehra Kamal, Scientist Grade- I and Head, attended National Streening Committee meeting for BND on 11<sup>th</sup> February, 2026
- Dr. Charu Mehra Kamal, Scientist Grade- I and Head, virtually attended “National Conference on Safety of Women at Workplace, 2026” held at Vigyan Bhawan on 14<sup>th</sup> February, 2026.
- Ms. Gurminder Bindra, Scientist Grade- III and Dr. Birendra Kumar, Junior Scientist, carried out joint inspection of M/s. Symbiotec Phamalab Private Ltd. (Biotech R& D) Mhow, Indore, Madhya Pradesh for the grant of permission in Form CT-11 to manufacture applied drug substance and drug product for examination, test and analysis on 24<sup>th</sup> and 25<sup>th</sup> February, 2026.
- Dr. Gauri Misra, Scientist Grade-I and Head, as an expert, attended the 45<sup>th</sup> MedTech Mitra meeting virtually held on 26<sup>th</sup> February, 2026 organized by ICMR (HQ).
- Dr. Gauri Misra, Scientist Grade-I and Head, invited as a special guest and expert speaker to deliver a talk on “Molecular Diagnostics Development for Infectious diseases, A way Ahead” followed by an interactive session with the students, organized by Department of Biotechnology, Delhi Technological University (DTU) Delhi, on 2<sup>nd</sup> March, 2026.
- Dr. Shikha Yadav, Scientist Grade-I & Head, received invitation from Dr. Montip Gettayacamin, Regional Director for Southeast Asia, AAALAC International as Council member, for conducting site visit and she assessed three units in India from 2<sup>nd</sup> to 3<sup>rd</sup> March, 5<sup>th</sup> March and 9<sup>th</sup> March, 2026 to evaluate their institutional animal care and use program for accreditation purposes.
- Dr. Gauri Misra, Scientist Grade-I and Head, chaired the session for the 9<sup>th</sup> Edition of World Cancer Congress -2026 held at JNU Convention Centre, New Delhi, India, from 20<sup>th</sup> to 21<sup>st</sup> March, 2026.
- Dr. Gauri Misra, Scientist Grade-I and Head, invited as a speaker and delivered a talk on “From spindles to singles: Multifaceted role of MASTL in Breast Cancer progression” during 9<sup>th</sup> Edition of World Cancer Congress -2026 held at JNU Convention Centre, New Delhi, India, on 21<sup>st</sup> March, 2026.
- Ms. Rashmi Shrivastava, Scientist Grade III, presented a poster on the role of FNBP4 in breast cancer at the 9<sup>th</sup> World Cancer Congress organised by ARJYOPA at JNU Convention Centre on 20<sup>th</sup> to 21<sup>st</sup> March, 2026.
- Ms. Rashmi Shrivastava, Scientist Grade- III, delivered a distinguished lecture at C-CAMP, Bangalore, on the topic “The Regulatory Spectrum: Decoding the m/z of Indian Drug Regulation during their Hands-on Training in Omics Research and Analytical Techniques on 27<sup>th</sup> March, 2026.
- Dr. Gauri Misra, Scientist Grade- I and Head, nominated for preparation of SOPs for biosimilars validation for cancer by Immunohistochemistry, RT-PCR or PCR based methods for commercial kits at ICMR, NICHDR.
- Ms. Rashmi Shrivastava, Scientist Grade- III & Ms. Sanchi Goel, Junior Scientist, represented NIB in the First National Quality Conclave 2026 organised by the Department for Promotion of Industry and Internal Trade (DPIIT), Government of India, in collaboration with Quality Council of India (QCI) from 22<sup>nd</sup> to 23<sup>rd</sup> February, 2026 in New Delhi.
- Dr. Charu Mehra Kamal, Scientist Grade -I and Head, attended 2<sup>nd</sup> National Steering Committee (NSC) meeting for Bharatiya Nirdeshak Dravyas (BNDs) at CSIR-NPL on 11<sup>th</sup> February, 2026.
- Dr. Charu Mehra Kamal, Scientist Grade -I and Head, attended a Meeting with IPC Ghaziabad on 24<sup>th</sup> February, 2026 to Discuss Coordination Modalities for development of Biological reference Standards in line with 39<sup>th</sup> NIB



- Dr. Charu Mehra Kamal, DD (QC) attended meeting on 18<sup>th</sup> March, 2026 at NIB with WHO officials to discuss modalities for conducting workshops by NIB through SEARN.
- Dr. Manoj Kumar, Scientist Grade-III, attended the training on Standard Performance Evaluation Protocol for Dengue NS1 RDT on 24<sup>th</sup> March, 2026 at ICMR headquarters.
- Ms. Y. Madhu, Scientist Grade-III & Head, MTL, attended an Expert Committee Meeting online, held on 30<sup>th</sup> March, 2026 at ICMR (HQ), New Delhi, organized by ICMR-CDSCO, to discuss the performance evaluation / Quality Control testing of in vitro diagnostic kits for Malaria as per the “ICMR-CDSCO standard evaluation protocol”.

## EVENTS UNDER ANNUAL CAPACITY BUILDING PLAN-2025-26 FOR NIB OFFICIALS

- Lecture on “Analytical and Regulatory Aspects of Biosimilars and Biologics Characterization held on 15<sup>th</sup> January, 2026, governed with an invited talk by Dr. Mohana Krishna Reddy Mudiam Director Institute of Pesticide Formulation Technology (IPFT), Department of Chemicals & Petrochemicals, Ministry of Chemicals & Fertilizers, Govt. of India, Gurugram-Haryana.
- Lecture on “Quality Risk Management -Update” held on 22<sup>nd</sup> January, 2026, governed with a special talk by Ms. Shalini Tewari - Scientist Grade-III, Head- Quality Management Unit (QMU), NIB.
- Two-Days Training cum-workshop on “Inter Laboratory Comparison, Proficiency Testing (ILC, PT) and Evaluation of Scores for NIB Laboratory staff; held on 10<sup>th</sup> to 11<sup>th</sup> February, 2026, involving 28 Nominated Regular staff members conducted with joint resource person support of National Institute of Training for Standardization NITS- (BIS).
- Two-Days training cum-workshop on “Pipette Leak Testing & Calibration Analyses” at NIB-Campus, held from 24<sup>th</sup> to 25<sup>th</sup> February 2026,

## TRAININGS IMPARTED

- Conducted a five-day training programme on "Application of Reverse Phase High-Performance Liquid Chromatography (HPLC) for Identification and Potency Testing of Human Insulin." A total of 02 participants (01 Scientist from ICMR-NIRRH & 01 M.Sc. Biotechnology student from IMS Ghaziabad) attended the programme.
- Conducted a two-week National Skill Development and Hands-on Training in Quality Control of Biologicals for 23 postgraduate students from Mizoram University, Mizoram, and Nagaland University, Nagaland.

## PUBLICATIONS

- Kumar S, Himanshu, Gaur P, Ahmad S, Puri P, Raj VS, Pandey RP. Microbiota transplantation as a future novel therapeutic strategy approach. Diseases. 2026; 14:42. doi:10.3390/diseases14020042.
- Sharma P, Sharma RD, Sarkar B, Panwar V, Das M, Singh L, Jain N, Chaturvedi S, Mehra L, Rathee A, Sharma S, Foo S, Lee A, Kumar NP, Das P, Viswanathan V, Kornfeld H, Howland SW, Babu S, Nandicoori V, Singhal A, Kumar D. Ly6G<sup>+</sup> granulocytes-derived IL-17 limits protective host responses and promotes tuberculosis pathogenesis. eLife. 2024;13:RP100966
- The Science India (March 2026) has published an article showcasing the eminent contributions by Dr. Neelima Mishra, Dr. Gauri Misra and Ms. Shalini Tewari on “The Silent Guardian of Biological Medicines”, highlighting the vital role of the National Institute of Biologicals (NIB), Noida, ensuring the safety, quality, and efficacy of the biological products.
- Venkatesh Anand Iyer, Golam Md Mowazzim, Sukhen Majhi, Jaipal Meena, Dr. Manjula Kiran, Dr. Farha, Dr. Shikha Yadav and Dr. Harit Kasana “Advancing Rabies Control in India: The Crucial Role of QC in Vaccine Provision and Public Health Initiatives”. Accepted for publication in Research Journal of Pharmacy and Technology in Year: 2026, Volume: 19, Issue: 6.



**ACKNOWLEDGEMENT :** Newsletter Editorial Team acknowledges the contribution of all the staff members of NIB.



## National Institute of Biologicals

A-32, Sector-62, Near NH-24, NOIDA - 201309, Uttar Pradesh

Tel: 0120-2400072, 2400022 Fax : 0120-2403014

NIB website: <http://nib.gov.in>, Email: [info@nib.gov.in](mailto:info@nib.gov.in)

**For any other Information/ Suggestions/ Queries related to Newsletter kindly contact:**

Dr. Suresh Kumar, Associate Editor, Email : [suresh.kumar@nib.gov.in](mailto:suresh.kumar@nib.gov.in).